#6 - Altimmune (NASDAQ:ALT)
Many of the stocks on this list are those of large-cap companies. That makes sense since these companies have the financial resources to deploy into an emerging area such as GLP-1. Altimmune Inc. (NASDAQ: ALT) is an exception. With just a $450.58 million market cap as of this writing, the company is a small-cap stock that trades at just $6.41 per share.
Altimmune’s GLP-1 candidate, pemvidutide, is similar to the current offerings from Novo Nordisk and Eli Lilly. However, early reports show that it is more effective at preserving lean muscle mass. That said, the company is actively looking for partners to help it advance pemvidutide through clinical trials.
Altimmune is not for the risk-averse investor. The company is not yet profitable and is not generating significant revenue. But if you’re comfortable with a speculative bet in the GLP-1 space, Altimmune could be a buy low, sell high candidate to fatten your portfolio years down the road.
About Altimmune
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Read More - Current Price
- $7.79
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $18.80 (141.3% Upside)
